Literature DB >> 18433301

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.

Michael S Ominsky1, Xiaodong Li, Frank J Asuncion, Mauricio Barrero, Kelly S Warmington, Denise Dwyer, Marina Stolina, Zhaopo Geng, Mario Grisanti, Hong-Lin Tan, Timothy Corbin, James McCabe, William S Simonet, Hua Z Ke, Paul J Kostenuik.   

Abstract

INTRODUCTION: Ovariectomy (OVX) results in bone loss caused by increased bone resorption. RANKL is an essential mediator of bone resorption. We examined whether the RANKL inhibitor osteoprotegerin (OPG) would preserve bone volume, density, and strength in OVX rats.
MATERIALS AND METHODS: Rats were OVX or sham-operated at 3 mo of age. Sham controls were treated for 6 wk with vehicle (Veh, PBS). OVX rats were treated with Veh or human OPG-Fc (10 mg/kg, 2/wk). Serum RANKL and TRACP5b was measured by ELISA. BMD of lumbar vertebrae (L(1)-L(5)) and distal femur was measured by DXA. Right distal femurs were processed for bone histomorphometry. Left femurs and the fifth lumbar vertebra (L(5)) were analyzed by muCT and biomechanical testing, and L(6) was analyzed for ash weight.
RESULTS: OVX was associated with significantly greater serum RANKL and osteoclast surface and with reduced areal and volumetric BMD. OPG markedly reduced osteoclast surface and serum TRACP5b while completely preventing OVX-associated bone loss in the lumbar vertebrae, distal femur, and femur neck. Vertebrae from OPG-treated rats had increased dry and ash weight, with no significant differences in tissue mineralization versus OVX controls. muCT showed that trabecular compartments in OVX-OPG rats had significantly greater bone volume fraction, vBMD, bone area, trabecular thickness, and number, whereas their cortical compartments had significantly greater bone area (p < 0.05 versus OVX-Veh). OPG improved cortical area in L(5) and the femur neck to levels that were significantly greater than OVX or sham controls (p < 0.05). Biomechanical testing of L(5) and femur necks showed significantly greater maximum load values in the OVX-OPG group (p < 0.05 versus OVX-Veh). Bone strength at both sites was linearly correlated with total bone area (r(2) = 0.54-0.74, p < 0.0001), which was also significantly increased by OPG (p < 0.05 versus OVX).
CONCLUSIONS: OPG treatment prevented bone loss, preserved trabecular architecture, and increased cortical area and bone strength in OVX rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18433301     DOI: 10.1359/jbmr.080109

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  43 in total

1.  High fat diet attenuates hyperglycemia, body composition changes, and bone loss in male streptozotocin-induced type 1 diabetic mice.

Authors:  Adriana Lelis Carvalho; Victoria E DeMambro; Anyonya R Guntur; Phuong Le; Kenichi Nagano; Roland Baron; Francisco José Albuquerque de Paula; Katherine J Motyl
Journal:  J Cell Physiol       Date:  2017-08-04       Impact factor: 6.384

2.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

3.  Adenoviral vector-mediated overexpression of osteoprotegerin accelerates osteointegration of titanium implants in ovariectomized rats.

Authors:  G Yin; J Chen; S Wei; H Wang; Q Chen; Y Lin; J Hu; E Luo
Journal:  Gene Ther       Date:  2015-04-14       Impact factor: 5.250

4.  Characterization of Regulatory Extracellular Vesicles from Osteoclasts.

Authors:  N Huynh; L VonMoss; D Smith; I Rahman; M F Felemban; J Zuo; W J Rody; K P McHugh; L S Holliday
Journal:  J Dent Res       Date:  2016-02-23       Impact factor: 6.116

5.  [Research progress in the osteogenetic mechanism of strontium].

Authors:  Ning-Ying Zhong; Li-Ping Wang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-12-01

6.  RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.

Authors:  Tara L Aghaloo; Simon Cheong; Olga Bezouglaia; Paul Kostenuik; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

7.  Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study.

Authors:  Graeme M Campbell; Michael S Ominsky; Steven K Boyd
Journal:  Osteoporos Int       Date:  2010-05-18       Impact factor: 4.507

8.  RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.

Authors:  Nicolas Bonnet; Lucie Bourgoin; Emmanuel Biver; Eleni Douni; Serge Ferrari
Journal:  J Clin Invest       Date:  2019-05-23       Impact factor: 14.808

9.  A novel in vivo gene transfer technique and in vitro cell based assays for the study of bone loss in musculoskeletal disorders.

Authors:  Dennis J Wu; Neha Dixit; Erika Suzuki; Thanh Nguyen; Hyun Seock Shin; Jack Davis; Emanual Maverakis; Iannis E Adamopoulos
Journal:  J Vis Exp       Date:  2014-06-08       Impact factor: 1.355

10.  Commitment to the osteoblast lineage is not required for RANKL gene expression.

Authors:  Carlo Galli; Qiang Fu; Wenfang Wang; Bjorn R Olsen; Stavros C Manolagas; Robert L Jilka; Charles A O'Brien
Journal:  J Biol Chem       Date:  2009-03-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.